
1. j trop med hyg. 2012 dec;87(6):996-1003. doi: 10.4269/ajtmh.2012.12-0202. epub
2012 oct 8.

surveillance molecular markers plasmodium falciparum resistance to
sulphadoxine-pyrimethamine 5 years change malaria treatment policy
in ghana.

duah no(1), quashie nb, abuaku bk, sebeny pj, kronmann kc, koram ka.

author information: 
(1)noguchi memorial institute medical research, legon, accra, ghana.
nduah@noguchi.mimcom.org

in 2005, sulphadoxine-pyrimethamine (sp) became drug choice for
intermittent preventive treatment plasmodium falciparum malaria pregnancy
(iptp) ghana. reports suggest use sp others treat uncomplicated
malaria. increased use sp, prevalence mutations the
genes, dihydrofolate reductase (dhfr), dihydropteroate synthetase (dhps),
linked sp resistance p. falciparum determined. blood samples 945 
children uncomplicated malaria collected nine sites 2003 2010
were analyzed using polymerase chain reaction restriction fragment length
polymorphism. prevalence dhfr triple dhfr plus dhps quadruple
mutations showed significant increase trend 2003 2010 (χ(2) = 18.78, p
< 0.001, χ(2) = 15.11, p < 0.001, respectively). dhps double mutant g437 +
e540 prevalence low (1.12%) caused low prevalence e540.
our findings show wide use sp ghana therefore use iptp
needs closely monitored.

doi: 10.4269/ajtmh.2012.12-0202 
pmcid: pmc3516103
pmid: 23045251  [indexed medline]

